Latest news with #PhilipMorrisInternationalInc.
Hans India
23-05-2025
- Business
- Hans India
PMI in India Hails Track & Trace (T&T) Mechanism Roll Out in the country Aimed At Curbing Illicit Tobacco Trade
India, 2025: Philip Morris International Inc.'s (PMI) India affiliate, IPM India, today hailed India's decision to roll out pack-level Track and Trace (T&T) as a game-changing move against illicit tobacco trade and a major step towards modernizing regulatory enforcement. Approved under Section 148A of the Central Goods and Services Tax (CGST) Act, this reform marks a bold move to protect revenue, tighten enforcement, and bring greater transparency and accountability to India's tobacco market. Starting with cigarette packs, the government has chosen a smart, high-impact strategy to curb illicit tobacco trade. The proposed mechanism may incorporate Unique Identification Markings on packs, which will enable enforcement agencies to easily distinguish tax-paid products from illegal ones—strengthening oversight across retail shelves, supply chains, and field operations. The proposed T&T mechanism will be a practical, real-world solution designed for immediate impact—and a critical foundation for a more modern, technology-driven regulatory system. With operations across multiple markets, PMI brings deep, practical experience from some of the world's most advanced T&T systems & implemented it voluntarily in 140+ markets worldwide. In the European Union, PMI operates under the Tobacco Products Directive, where every pack is digitally tagged and monitored through the supply chain. Similar systems have been successfully deployed in UK, Russia, Jordan, Gulf Cooperation Council (GCC), where PMI has worked with national authorities to build scalable, locally adapted traceability frameworks. Across all markets, the outcome have been consistent: better visibility, stronger compliance, and measurable reductions in illicit trade. Illicit tobacco trade isn't just a revenue problem—it's a public health threat, a blow to lawful businesses, and fuel for the informal economy. Track and Trace is a proven tool for modernizing supply chains and enforcement. By clearly separating legal from illegal products, it not only protects consumers but also secures tax collections and promotes a level playing field for compliant operators. Emphasising the need for a stringent T&T mechanism, Navaneel Kar, Managing Director, IPM India said, 'This is a landmark reform and a visionary step towards a cleaner, more modern, and a transparent market. With thoughtful execution, India's T&T system can reshape the fight against illicit tobacco trade—boosting public trust, strengthening government revenues, and accelerating the modernization of enforcement practices. Eliminating illicit tobacco trade has been a longstanding priority for us and remains integral to our broader efforts in driving operational excellence and building a sustainable future. PMI has long invested in technologies that protect supply chain integrity globally, and we are committed to partnering with the Indian government to make this initiative a success.'India's move to ratify the illicit tobacco trade protocol, also aligns with international standards. T&T is a core requirement under Article 15 of the WHO Framework Convention on Tobacco Control (FCTC) and the 2014 Protocol to Eliminate Illicit Trade in Tobacco Products. As one of the world's largest tobacco markets and a key transit hub, India's leadership sends a powerful global signal toward modernization and digital oversight. Implementation of the proposed T&T systems should allow interoperability, facilitate innovation and the optimization of enforcement activities along with independent, cost-effective solutions that do not disrupt the manufacturing and distribution environment. But technology alone won't deliver results. Collaboration is essential. Effective systems require close cooperation between governments, industry players, and technology providers. Solutions must be flexible enough to reflect India's enforcement realities and dynamic enough to stay ahead of evolving risks. India's T&T mechanism rollout is just the beginning. It sets the stage for a broader modernization of supply chain regulation—expanding across more products, deeper distribution layers, and even into other sectors facing similar challenges. With smart partnerships and sustained innovation, India can build one of the world's most resilient, transparent, and future-ready regulatory ecosystems.
Yahoo
01-05-2025
- Business
- Yahoo
Philip Morris International's (NYSE:PM) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with Philip Morris International Inc.'s (NYSE:PM) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Importantly, our data indicates that Philip Morris International's profit was reduced by US$2.6b, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Philip Morris International doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Unusual items (expenses) detracted from Philip Morris International's earnings over the last year, but we might see an improvement next year. Because of this, we think Philip Morris International's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Philip Morris International, you'd also look into what risks it is currently facing. You'd be interested to know, that we found 3 warning signs for Philip Morris International and you'll want to know about them. This note has only looked at a single factor that sheds light on the nature of Philip Morris International's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
25-03-2025
- Health
- Yahoo
Why the FDA is right about Zyn
The U.S. Food and Drug Administration recently authorized the marketing of 20 nicotine pouch products under the Zyn brand, including flavors like Wintergreen and the "unflavored" Chill. That authorization sparked a new round of proposed legislation, trend pieces and frustration. Meanwhile, the stock price for Philip Morris International Inc., which manufactures the smokeless product, has caught fire. Tobacco-control professionals fought long and hard for comprehensive legislation that would give FDA regulatory oversight over tobacco products and nicotine products that do not make therapeutic claims. But Zyn has proven to be especially controversial given a series of buzzy stories about its use by young people and its seeming popularity on social media sites like TikTok. So-called 'Zynfluencers' have led to fears that a new and youthful crowd could be looking to exploit the pouches for everything from long work days to clubbing. Most recently, Carrie Battan over at The New Yorker wrote about how Zyn pouches were becoming a 'staple for American dudes' in a dispatch announcing 'the new nicotine gold rush.' The good news is some of these fears may be overblown, especially fears about abuse by young people. The reality is that after being available on the U.S. market for 10 years, only 2.4% of U.S. high school students had used a nicotine pouch in the previous 30 days in 2024 (as compared to 7.8 % for electronic cigarettes). Zyn, like other new 'nicotine pouch' products, contains no tobacco. It consists of a pouch, a bit like a mini teabag, containing powdered nicotine, along with a few other ingredients such as noncaloric sweeteners and flavors. Each tin contains 15 pouches which are typically placed under the upper lip for up to an hour to allow the nicotine to be absorbed through the lining of the mouth. The amount of nicotine delivered by the 3 mg and 6 mg strength pouches is slightly higher than that delivered by 2 mg and 4 mg nicotine gum, but the peak is lower and slower than the nicotine delivered by a cigarette. In deciding whether to authorize these products, the FDA has to scrutinize a very detailed application and assess whether it is 'appropriate for the protection of public health' to allow the products to be sold on the U.S. market. This involves weighing the likely risks and benefits to the population, including youth, those not currently using any tobacco products and existing users. The 68-page summary of the FDA's January Zyn decision noted that the levels of 42 potentially harmful chemicals were so low in Zyn as to be undetectable. FDA officials concluded that the health risks from Zyn pouches are likely lower than potential risks from using snus (low toxicant smokeless tobacco) and the FDA has already concluded that some snus brands are significantly less harmful than cigarettes. In their summary decision statement, FDA also referred to data produced by the applicants from studies on the effects of Zyn on existing tobacco users. Officials mentioned that in one study, more than 60% of existing tobacco users reported using Zyn to help reduce or quit smoking. Another study found that nearly a quarter of existing tobacco users completely switched to Zyn. While the manufacturers of Zyn are not claiming that Zyn is a medicinal smoking cessation aid, the fact that relatively few young people are taking up Zyn use, whereas a meaningful proportion of smokers are likely to switch to the product, suggests that the benefits are likely to outweigh the risks. This, combined with the very low toxicant delivery profile of Zyn (particularly compared to cigarettes), convinced the FDA that it is appropriate for public health for Zyn products to be marketed in the U.S. This is the FDA doing its job exactly as required by the 2009 Tobacco Control Act. The real controversy about this decision should be in relation to the length of time it took. Over 2,000 brands of cigarettes are currently available on the U.S. market. Each one emits thousands of toxic chemicals, including carcinogens that are inhaled directly into the lungs, with consequences we are all too familiar with. It is a good thing that smokers now have legal access to a product that can deliver the same drug many are already addicted to (nicotine) but with far lower health risks than cigarettes. The day before announcing Zyn's marketing authorization, FDA Center for Tobacco Products announced another proposed rule that could have a massive impact on public health: a product standard that would limit the amount of nicotine permissible in cigarettes to nonaddictive levels. The timing may not have been coincidental. This 'low-nicotine cigarette' standard must pass through many steps before it can be implemented. One factor that may be key to its success is a wide selection of legal, less harmful (nonsmoked) nicotine products for nicotine-addicted smokers looking to switch. Zyn could be just such a product. So yes, it may seem like authorizing another nicotine product — especially one with its own youthful cultural cachet — is a risky decision. But when evaluating all the factors, it actually makes sense. This article was originally published on
